On the evening of February 27, Touchstone International Medical Science Co.Ltd(688013) released the performance express of 2021. From January to December 2021, the company achieved an operating revenue of 214 million yuan, a year-on-year increase of 31.01%; The net profit attributable to the shareholders of the listed company was 434049 million yuan, a year-on-year increase of 24.2%; The net profit attributable to the owner of the parent company after deducting non recurring profits and losses was 31.455 million yuan, a year-on-year increase of 13.71%.
The company said that in 2021, the company overcame the impact of the epidemic, continued to increase R & D investment, promoted technological innovation and product iteration, actively responded to market changes, continuously expanded and expanded sales scale, continued to optimize cost control, sustained high growth and achieved high-quality development on the premise of ensuring profitability.
In addition, in 2021, the impact amount of share based payment expenses caused by the implementation of the 2021 restricted stock incentive plan was 205933 million yuan. Without considering the impact of share based payment expenses, the net profit attributable to the shareholders of the listed company was 639983 million yuan, an increase of 83.12% year-on-year; The net profit attributable to shareholders of listed companies after deducting non recurring profits and losses was 520483 million yuan, a year-on-year increase of 88.16%.
